Hepatitis E cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatitis E}} | {{Hepatitis E}} | ||
{{CMG}}; {{AE}} {{JS}} | {{CMG}}; {{AE}} {{JS}} | ||
==Overview== | ==Overview== | ||
Hepatitis E is is usually self-limited in | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 12: | Line 11: | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
Revision as of 18:58, 25 August 2014
|
Hepatitis E Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Hepatitis E cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis E cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hepatitis E cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Hepatitis E is is usually self-limited in